Document:

EX-10.15

 Exhibit 10.15 

SUPPLEMENT TO THE TERADYNE, INC. 

1996 EMPLOYEE STOCK PURCHASE PLAN 

(as amended as of January 1, 2019) 

DANISH SECTION 

Preamble 
 The purpose of
this Supplement (the “Supplement”) to the Teradyne, Inc. 1996 Employee Stock Purchase Plan (the “Plan”), as amended, modified or restated (the Plan as modified by this Supplement in accordance with the terms hereof, the
“Danish Subplan”), is to allow Teradyne, Inc. (the “Company”) to grant an option to purchase shares of the Company’s Common Stock at a discount to certain employees and officers of its Danish subsidiaries, (“Teradyne
Denmark Subsidiaries”) in a manner that will comply with certain conditions set forth in the Danish Share Option Act (aktieoptionsoloven) as amended on 6 December 2018 and effective 1 January 2019 (“Danish Share Option
Act”). Capitalized terms used herein but not elsewhere defined shall have the same meanings as those in the Plan. Unless as set forth herein, all of the terms of the Plan shall apply to grants under this Danish Subplan. 

This Danish Subplan was authorized and approved by an officer of the Company on December 4, 2019, pursuant to authority delegated to such
officer by the Compensation Committee of the Board of Directors (the “Committee”). The Danish Subplan is a new equity incentive scheme designed to comply with the Danish Share Option Act. 

Eligibility 
 Only
employees and officers of Teradyne Denmark Subsidiaries are eligible to receive options to purchase shares of Common Stock under this Danish Subplan. 

Effect of Termination of Employment 

The right to purchase shares under this Danish Subplan will terminate upon termination of employment, except in the event of termination due
to a lay off or retirement during the last three months of a Payment Period (as set forth in Article 14 of the Plan). 
 In all other
circumstances, the right to purchase shares will terminate as of the date of termination of employment. For purposes of participation in the Plan, a participant’s status as an employee will be considered terminated as of the date the
participant is no longer actively providing services to Teradyne Denmark Subsidiaries (regardless of the reason for such termination or the terms of the participant’s employment agreement, if any) and will not be extended by any notice period
(e.g., the participant’s period of service would not include any contractual notice period or any period of “garden leave” or similar period mandated under Danish employment laws or the terms of the participant’s
employment agreement, if any). The Committee shall have the exclusive discretion to determine when the participant is no longer actively providing services for purposes of participation in the Plan(including whether the participant may still be
considered to be providing services while on a leave of absence). 
 A participant’s employment shall be considered as continuing
uninterrupted during any bona fide leave of absence (such as those attributable to illness or military obligations) provided that the period of such leave does not exceed 90 days or, in the case of an employee, if longer, any period during which the
participant’s right to reemployment is guaranteed by Danish law. A bona fide leave of absence with the written approval of the Committee shall not be considered an interruption of employment, provided that such written approval contractually
obligates Teradyne Denmark Subsidiaries to continue the employment of the participant after the approved period of absence. 

  
 1Exhibit_4_3

		

			Exhibit 4.3

		

		
			DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934
		

		
			The following description of the common stock, par value $0.0001 per share, of Natera, Inc. (“us,” “our,” “we,” or the “Company”), which is the only security of the Company registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),  summarizes certain information regarding the Common Stock in our amended and restated certificate of incorporation, our amended and restated by-laws and applicable provisions of Delaware general corporate law (the “DGCL”), and is qualified by reference to our amended and restated certificate of incorporation and our amended and restated by-laws, which are incorporated by reference as Exhibit 3.1 and Exhibit 3.2, respectively, to the Annual Report on Form 10-K for the fiscal year ending December 31, 2019. 
		

		
			Our authorized capital stock consists of 750,000,000 shares of common stock, par value $0.0001 per share, and 50,000,000 shares of preferred stock, par value, $0.0001 per share.
		

		
			Common Stock 
		

		
			Our common stock is listed on the Nasdaq Global Select Market under the symbol “NTRA”. 
		

		
			Voting Rights. Each holder of common stock is entitled to one vote per share on all matters submitted to a vote of stockholders. We have not provided for cumulative voting in the election of directors. 
		

		
			Dividends. Subject to preferences that may apply to shares of preferred stock outstanding at the time, the holders of outstanding shares of our common stock are entitled to receive dividends out of assets legally available at the times and in the amounts that our board of directors may determine from time to time. 
		

		
			Liquidation and Dissolution. In the event of our liquidation, dissolution or winding-up, the holders of common stock are entitled to share ratably in all assets remaining after payment of all liabilities and the liquidation preferences of any outstanding preferred stock. 
		

		
			Other Rights. Holders of common stock have no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to our common stock. 
		

		
			Anti-Takeover Effects of Provisions of Delaware Law and Our Certificate of Incorporation and Bylaws 
		

		
			Certain provisions of the DGCL, our amended and restated certificate of incorporation and our amended and restated bylaws could have the effect of delaying, deferring or discouraging another party from acquiring control of us. These provisions, which are summarized below, are expected to discourage certain types of coercive takeover practices and inadequate takeover bids. These provisions are also designed, in part, to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging such proposals, including proposals that are priced above the then-current market value of our common stock, because, among other reasons, the negotiation of such proposals could result in an improvement of their terms.Exhibit_10_5_5

		

			Exhibit 10.5.5

		

		

			Confidential 

		

		

			 

		

		

			THE SYMBOL “[*]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

		

		

			 

		

		
			FIFTH AMENDMENT TO SUPPLY AGREEMENT
		

		
			 
		

		
			This Fifth Amendment to Supply Agreement (the “Fifth Amendment”) is effective as of the date last signed below (the “Fifth Amendment Date”) between Illumina, Inc., a Delaware corporation having a place of business at 5200 Illumina Way, San Diego, CA  92122 ("Illumina") and Natera, Inc., having a place of business at 201 Industrial Road, Suite 410, San Carlos, CA  94070 (“Customer”).   Customer and Illumina may be referred to herein as “Party” or “Parties.” 
		

		
			 
		

		
			WHEREAS, Illumina and Customer are Parties to a Supply Agreement having an Effective Date of August 16, 2013, and amended on September 18, 2014, September 23, 2015, June 8, 2016, and January 3, 2019 (“Agreement”); 
		

		
			 
		

		
			WHEREAS, the Parties have agreed upon certain amendments to add products available for purchase under the Agreement; 
		

		
			 
		

		
			NOW, THEREFORE, in consideration of the mutual promises and covenants hereinafter set forth, the Parties hereto agree to amend the Agreement as follows:
		

		
			 
		

			
	
			
				 1.
			

			
	
			
			Illumina agrees that it shall [*]. For the avoidance of doubt, beginning in calendar year 2021 and through the end of the Term, Illumina may adjust list prices in accordance with Section 7(a) of the Agreement.

		
			 
		

			
	
			
				 2.
			

			
	
			
			Amendment to Exhibit B – Illumina Hardware and Consumables.  Exhibit B of the Agreement is hereby amended as follows:

		
			 
		

			
	
			
				 a)
			

			
	
			
			The products listed in the attached Quotation No. 4246299 and Quotation 4246655 (each a “Fifth Amendment Quote” and, together, the “Fifth Amendment Quotes”) are added to Exhibit B as Illumina Hardware and Consumables.  

			
	
			
				 b)
			

			
	
			
			The current pricing and discounts for such products are contained exclusively in the Fifth Amendment Quotes, subject to Section 7(a) of the Agreement, provided that (i) the pricing and discounts contained in Quotation No. 4246655 shall expire on December 18, 2019, (ii) the pricing and discounts contained in Quotation No. 4246299 shall expire on January 9, 2020, (iii) after such expiration, Illumina shall issue a new one-year standing quotation covering all of the products listed in the Fifth Amendment Quotes and such quotation shall provide a discount for the included Hardware that is not less than [*] off of the list price and a discount for the included Consumables equal to [*] off of the list prices, and (iv) the discounts associated with any purchases of products contained in the Fifth Amendment Quotes after expiration of the standing quotation referenced in subpart (iii) shall be in accordance with Illumina’s standard discounting rates for such products at that time; provided, however that such discounts shall be no less favorable than the discounts set forth in the table below.  Notwithstanding any other language in Exhibit B, no additional discounts shall apply unless otherwise specified by Illumina at a later date.

		
			 
		

		

		 

	
					
						

					
						Overall Sequencing Consumable Spend

					
					
						[*]

					
					
						[*]

				
	
					
						[*]

					
					
						[*]

					
					
						[*]

				
	
					
						[*]

					
					
						[*]

					
					
						[*]

				
	
					
						[*]

					
					
						[*]

					
					
						[*]

				
	
					
						[*]

					
					
						[*]

					
					
						[*]

				

		
			 
		

		
			“Overall Sequencing Consumable Spend” is determined quarterly at the first day of each calendar quarter (i.e., January 1, April 1, July 1, October 1), and equals (1) the total amount (minus freight, taxes, and any product credits or offsets) Illumina has invoiced Customer for shipments of all Sequencing Consumables delivered to Customer during the 12 calendar month period that immediately precedes such first day of a calendar quarter under this Agreement, which includes Sequencing Consumables purchased under this Agreement and Sequencing Consumables purchased from Illumina outside of this Agreement.  Overall Sequencing Consumable Spend does not include, by way of example, amounts invoiced for array products, Test Fees, Services, or Hardware.
		

		
			 
		

		
			“Sequencing Consumable” means a Consumable [*].
		

		
			 
		

			
	
			
				 c)
			

			
	
			
			The terms contained in the last paragraph on page 8 of the Quotation No. 4246299 and page 4 of Quotation 4246655 (including, in each case, the linked materials) shall not apply to the products contained in the Fifth Amendment Quotes.  The products contained in the Fifth Amendment Quotes shall be governed by the Agreement, as applicable, and the remaining terms of the Fifth Amendment Quotes.

		
			 
		

			
	
			
				 3.
			

			
	
			
			 No License.  For the avoidance of doubt, no license of other right is being granted in this Fifth Amendment under or to use any Application Specific IP or Other IP, including, without limitation, U.S. Patent No. [*].

		
			 
		

			
	
			
				 4.
			

			
	
			
			Entire Agreement. Except as expressly stated herein, this Fifth Amendment does not alter any term or condition of the Agreement. This Fifth Amendment represents the entire agreement between the Parties regarding the subject matter hereof and supersedes all prior discussions, communications, agreements, and understandings of any kind and nature between the Parties regarding the subject matter hereof.

		
			 
		

			
	
			
				 5.
			

			
	
			
			Reference to Agreement. On and after the Fifth Amendment Date, each reference in the Agreement to “this Agreement”, “hereunder”, or words of like import referring to the Agreement shall mean and be a reference to the Agreement as modified by this Fifth Amendment.

		
			 
		

			
	
			
				 6.
			

			
	
			
			Governing Law.  This Fifth Amendment and performance by the Parties hereunder shall be construed in accordance with the laws of the State of California, U.S.A., without regard to provisions on the conflicts of laws.

		
			 
		

			
	
			
				 7.
			

			
	
			
			Counterparts. This Fifth Amendment may be executed in one or more counterparts, and each of which shall be deemed to be an original, and all of which shall constitute one and the same instrument.

		
			 
		

		
			

		 

		

		
			IN WITNESS WHEREOF, the Parties hereto acknowledge and agree to the terms and conditions of this Fifth Amendment and have caused this Agreement to be executed by their respective duly authorized representatives to be effective as of the Fifth Amendment Date.
		

		
			 
		

		
			 
		

			
					
						Natera, Inc.:

					
					
						    

					
					
						Illumina, Inc.:

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						By: 

					
					
						/s/ John Fesko

					
					
						 

					
					
						By: 

					
					
						/s/ Mark Van Oene

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						Name:

					
					
						John Fesko

					
					
						 

					
					
						Name: 

					
					
						Mark Van Oene

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						Title: 

					
					
						SVP Business Development

					
					
						 

					
					
						Title: 

					
					
						Chief Commercial Officer

				
	
					
						 

					
					
						 

					
					
						 

					
					
						 

					
					
						 

				
	
					
						Date: 

					
					
						12/18/19

					
					
						 

					
					
						Date: 

					
					
						12/18/19

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00305-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00305-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00305-of-00352.parquet"}]]